{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:40:33Z","timestamp":1792701633102,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06333-8","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:16:37Z","timestamp":1792653397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of tocilizumab monotherapy for IgG4-related disease\u2013like features caused by idiopathic multicentric Castleman\u2019s disease: a case-based review"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-7069","authenticated-orcid":false,"given":"Koji","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-8977","authenticated-orcid":false,"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9073-9215","authenticated-orcid":false,"given":"Tomohiro","family":"Kaburaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0001-1078","authenticated-orcid":false,"given":"Kanako","family":"Shimanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4061-721X","authenticated-orcid":false,"given":"Koichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5765","authenticated-orcid":false,"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"6333_CR1","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/rheumatology\/keab634","volume":"61","author":"T Sasaki","year":"2022","unstructured":"Sasaki T, Akiyama M, Kaneko Y, Takeuchi T (2022) Immunoglobulin G4-related disease and idiopathic multicentric Castleman\u2019s disease: confusable immune-mediated disorders. Rheumatology (Oxford) 61:490\u2013501. https:\/\/doi.org\/10.1093\/rheumatology\/keab634","journal-title":"Rheumatology (Oxford)"},{"key":"6333_CR2","doi-asserted-by":"publisher","first-page":"e000432","DOI":"10.1136\/rmdopen-2017-000432","volume":"3","author":"T Sasaki","year":"2017","unstructured":"Sasaki T, Akiyama M, Kaneko Y et al (2017) Distinct features distinguishing IgG4-related disease from multicentric Castleman\u2019s disease. RMD Open 3:e000432. https:\/\/doi.org\/10.1136\/rmdopen-2017-000432","journal-title":"RMD Open"},{"key":"6333_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/jcp-2023-209280","volume":"79","author":"A Nishikori","year":"2025","unstructured":"Nishikori A, Nishimura MF, Fajgenbaum DC et al (2025) Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease. J Clin Pathol 79:43\u201349. https:\/\/doi.org\/10.1136\/jcp-2023-209280","journal-title":"J Clin Pathol"},{"key":"6333_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","volume":"79","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S et al (2020) The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 79:77\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216561","journal-title":"Ann Rheum Dis"},{"key":"6333_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","volume":"31","author":"H Umehara","year":"2021","unstructured":"Umehara H, Okazaki K, Kawa S et al (2021) The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31:529\u2013533. https:\/\/doi.org\/10.1080\/14397595.2020.1859710","journal-title":"Mod Rheumatol"},{"key":"6333_CR6","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","volume":"132","author":"F van Rhee","year":"2018","unstructured":"van Rhee F, Voorhees P, Dispenzieri A et al (2018) International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132:2115\u20132124. https:\/\/doi.org\/10.1182\/blood-2018-07-862334","journal-title":"Blood"},{"key":"6333_CR7","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","volume":"3","author":"AY Liu","year":"2016","unstructured":"Liu AY, Nabel CS, Finkelman BS et al (2016) Idiopathic multicentric Castleman\u2019s disease: a systematic literature review. Lancet Haematol 3:e163\u2013e175. https:\/\/doi.org\/10.1016\/S2352-3026(16)00006-5","journal-title":"Lancet Haematol"},{"key":"6333_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40266-024-01172-3","volume":"42","author":"M Akiyama","year":"2025","unstructured":"Akiyama M, Alshehri W, Saito K et al (2025) Pharmacological management of IgG4-related disease: From traditional to mechanism-based targeted therapies. Drugs Aging 42:111\u2013126. https:\/\/doi.org\/10.1007\/s40266-024-01172-3","journal-title":"Drugs Aging"},{"key":"6333_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00296-025-06065-1","volume":"46","author":"A Hammitzsch","year":"2026","unstructured":"Hammitzsch A, Ferraro N, Bachmann Q et al (2026) Long-term treatment patterns and outcomes in IgG4-related disease - a retrospective single-center cohort study focusing on rituximab. Rheumatol Int 46:33. https:\/\/doi.org\/10.1007\/s00296-025-06065-1","journal-title":"Rheumatol Int"},{"key":"6333_CR10","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","volume":"129","author":"DC Fajgenbaum","year":"2017","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A et al (2017) International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood 129:1646\u20131657. https:\/\/doi.org\/10.1182\/blood-2016-10-746933","journal-title":"Blood"},{"key":"6333_CR11","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.3346\/jkms.2024.39.e225","volume":"39","author":"IC Benlidayi","year":"2024","unstructured":"Benlidayi IC, Gupta L (2024) CAse-BAsed REview sTandards (CABARET): Considerations for authors, reviewers, and editors. J Korean Med Sci 39:e225. https:\/\/doi.org\/10.3346\/jkms.2024.39.e225","journal-title":"J Korean Med Sci"},{"key":"6333_CR12","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"6333_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"6333_CR14","doi-asserted-by":"publisher","first-page":"101458","DOI":"10.1016\/j.rmcr.2021.101458","volume":"34","author":"S Nakai","year":"2021","unstructured":"Nakai S, Murano M, Hiramatsu T et al (2021) Multicentric Castleman disease with infiltration of eosinophils to the lung. Respir Med Case Rep 34:101458. https:\/\/doi.org\/10.1016\/j.rmcr.2021.101458","journal-title":"Respir Med Case Rep"},{"key":"6333_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/PAS.0000000000000575","volume":"40","author":"T Zoshima","year":"2016","unstructured":"Zoshima T, Yamada K, Hara S et al (2016) Multicentric Castleman disease with tubulointerstitial nephritis mimicking IgG4-related disease: Two case reports: Two case reports. Am J Surg Pathol 40:495\u2013501. https:\/\/doi.org\/10.1097\/PAS.0000000000000575","journal-title":"Am J Surg Pathol"},{"key":"6333_CR16","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1093\/rheumatology\/keaa362","volume":"60","author":"M Kawano","year":"2021","unstructured":"Kawano M, Hara S, Yachie A et al (2021) HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease. Rheumatology (Oxford) 60:e3\u2013e4. https:\/\/doi.org\/10.1093\/rheumatology\/keaa362","journal-title":"Rheumatology (Oxford)"},{"key":"6333_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.12701\/yujm.2021.01039","volume":"39","author":"H-J Kim","year":"2022","unstructured":"Kim H-J, Hong Y-H (2022) Idiopathic multicentric Castleman disease presenting progressive reticular honeycomb infiltration of lung and immunoglobulin G and immunoglobulin G4 dominant hypergammaglobulinemia: a case report. J Yeungnam Med Sci 39:153\u2013160. https:\/\/doi.org\/10.12701\/yujm.2021.01039","journal-title":"J Yeungnam Med Sci"},{"key":"6333_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s13730-022-00751-w","volume":"12","author":"M Kawanishi","year":"2023","unstructured":"Kawanishi M, Kamei F, Sonoda H et al (2023) Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease. CEN Case Rep 12:242\u2013248. https:\/\/doi.org\/10.1007\/s13730-022-00751-w","journal-title":"CEN Case Rep"},{"key":"6333_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3390\/diagnostics14050476","volume":"14","author":"E Sawada","year":"2024","unstructured":"Sawada E, Shioda Y, Ogawa K et al (2024) A case of Castleman\u2019s disease with a marked infiltration of IgG4-positive cells in the renal interstitium. Diagnostics (Basel) 14:476. https:\/\/doi.org\/10.3390\/diagnostics14050476","journal-title":"Diagnostics (Basel)"},{"key":"6333_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.rmcr.2018.06.001","volume":"25","author":"Y Katsumata","year":"2018","unstructured":"Katsumata Y, Ikari J, Tanaka N et al (2018) Tocilizumab-effective multicentric Castleman\u2019s disease with infiltration of eosinophil and IgG4-positive plasma cells: A case report. Respir Med Case Rep 25:25\u201329. https:\/\/doi.org\/10.1016\/j.rmcr.2018.06.001","journal-title":"Respir Med Case Rep"},{"key":"6333_CR21","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.3390\/diagnostics12092261","volume":"12","author":"C-C Cheng","year":"2022","unstructured":"Cheng C-C, Chen Y-C, Hsu Y-H, Su K-Y (2022) Idiopathic multicentric Castleman disease with strikingly elevated IgG4 concentration in the serum and abundant IgG4-positive cells in the tissue: A case report. Diagnostics (Basel) 12:2261. https:\/\/doi.org\/10.3390\/diagnostics12092261","journal-title":"Diagnostics (Basel)"},{"key":"6333_CR22","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.2169\/internalmedicine.4793-24","volume":"64","author":"R Yoshimi","year":"2025","unstructured":"Yoshimi R, Nakajima H (2025) Idiopathic multicentric castleman\u2019s disease as a mimicker of IgG4-related disease. Intern Med 64:1788\u20131790. https:\/\/doi.org\/10.2169\/internalmedicine.4793-24","journal-title":"Intern Med"},{"key":"6333_CR23","doi-asserted-by":"publisher","unstructured":"Akiyama M, Alshehri W, Ishigaki S et al (2024) The immunological pathogenesis of IgG4-related disease categorized by clinical characteristics. Immunol Med 1\u201313. https:\/\/doi.org\/10.1080\/25785826.2024.2407224","DOI":"10.1080\/25785826.2024.2407224"},{"key":"6333_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13075-016-1064-4","volume":"18","author":"M Akiyama","year":"2016","unstructured":"Akiyama M, Yasuoka H, Yamaoka K et al (2016) Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease. Arthritis Res Ther 18:167. https:\/\/doi.org\/10.1186\/s13075-016-1064-4","journal-title":"Arthritis Res Ther"},{"key":"6333_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00795-016-0145-4","volume":"50","author":"A Manabe","year":"2017","unstructured":"Manabe A, Igawa T, Takeuchi M et al (2017) Immunohistochemical analysis of IgA expression differentiates IgG4-related disease from plasma cell-type Castleman disease. Med Mol Morphol 50:34\u201341. https:\/\/doi.org\/10.1007\/s00795-016-0145-4","journal-title":"Med Mol Morphol"},{"key":"6333_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.anl.2019.05.008","volume":"47","author":"K Matsushima","year":"2020","unstructured":"Matsushima K, Ohira S, Matsui H et al (2020) IgG4-related disease with pseudotumor formation in the larynx. Auris Nasus Larynx 47:305\u2013308. https:\/\/doi.org\/10.1016\/j.anl.2019.05.008","journal-title":"Auris Nasus Larynx"},{"key":"6333_CR27","doi-asserted-by":"publisher","first-page":"e70069","DOI":"10.1002\/lio2.70069","volume":"10","author":"N Weiss","year":"2025","unstructured":"Weiss N, Candelo E, Bridges M, Rutt A (2025) Insights into laryngeal Castleman disease: A comprehensive scoping review with a case study focus. Laryngoscope Investig Otolaryngol 10:e70069. https:\/\/doi.org\/10.1002\/lio2.70069","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"6333_CR28","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1136\/gut.2008.172908","volume":"58","author":"T Kamisawa","year":"2009","unstructured":"Kamisawa T, Shimosegawa T, Okazaki K et al (2009) Standard steroid treatment for autoimmune pancreatitis. Gut 58:1504\u20131507. https:\/\/doi.org\/10.1136\/gut.2008.172908","journal-title":"Gut"},{"key":"6333_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00296-017-3765-7","volume":"38","author":"S Yadlapati","year":"2018","unstructured":"Yadlapati S, Verheyen E, Efthimiou P (2018) IgG4-related disease: a complex under-diagnosed clinical entity. Rheumatol Int 38:169\u2013177. https:\/\/doi.org\/10.1007\/s00296-017-3765-7","journal-title":"Rheumatol Int"},{"key":"6333_CR30","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","volume":"106","author":"N Nishimoto","year":"2005","unstructured":"Nishimoto N, Kanakura Y, Aozasa K et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627\u20132632. https:\/\/doi.org\/10.1182\/blood-2004-12-4602","journal-title":"Blood"},{"key":"6333_CR31","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","volume":"21","author":"C Casper","year":"2015","unstructured":"Casper C, Chaturvedi S, Munshi N et al (2015) Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman disease. Clin Cancer Res 21:4294\u20134304. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0134","journal-title":"Clin Cancer Res"},{"key":"6333_CR32","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","volume":"78","author":"ZS Wallace","year":"2019","unstructured":"Wallace ZS, Zhang Y, Perugino CA et al (2019) Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis 78:406\u2013412. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214603","journal-title":"Ann Rheum Dis"},{"key":"6333_CR33","doi-asserted-by":"publisher","first-page":"102354","DOI":"10.1016\/j.autrev.2019.102354","volume":"18","author":"M Akiyama","year":"2019","unstructured":"Akiyama M, Kaneko Y, Takeuchi T (2019) Characteristics and prognosis of IgG4-related periaortitis\/periarteritis: A systematic literature review. Autoimmun Rev 18:102354. https:\/\/doi.org\/10.1016\/j.autrev.2019.102354","journal-title":"Autoimmun Rev"},{"key":"6333_CR34","doi-asserted-by":"publisher","first-page":"7594","DOI":"10.3390\/jcm13247594","volume":"13","author":"S Takanashi","year":"2024","unstructured":"Takanashi S, Kaneko Y (2024) Unmet needs and current challenges of rheumatoid arthritis: Difficult-to-treat rheumatoid arthritis and late-onset rheumatoid arthritis. J Clin Med 13:7594. https:\/\/doi.org\/10.3390\/jcm13247594","journal-title":"J Clin Med"},{"key":"6333_CR35","doi-asserted-by":"publisher","first-page":"1734761","DOI":"10.3389\/fimmu.2026.1734761","volume":"17","author":"X Ding","year":"2026","unstructured":"Ding X, Tao J, Xu C, Han Y (2026) Tocilizumab in the treatment of IgG4-related disease involving the carotid artery-case report and literature review. Front Immunol 17:1734761. https:\/\/doi.org\/10.3389\/fimmu.2026.1734761","journal-title":"Front Immunol"},{"key":"6333_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejim.2023.09.015","volume":"118","author":"V Batani","year":"2023","unstructured":"Batani V, Minici C, Sanvito F et al (2023) Interleukin-6 inhibition for the treatment of IgG4 related vasculitis. Eur J Intern Med 118:149\u2013151. https:\/\/doi.org\/10.1016\/j.ejim.2023.09.015","journal-title":"Eur J Intern Med"},{"key":"6333_CR37","doi-asserted-by":"publisher","first-page":"103296","DOI":"10.1016\/j.autrev.2023.103296","volume":"22","author":"M Akiyama","year":"2023","unstructured":"Akiyama M, Hayashi Y, Suzuki K et al (2023) Successful treatment of IgG4-related disease with tocilizumab monotherapy. Autoimmun Rev 22:103296. https:\/\/doi.org\/10.1016\/j.autrev.2023.103296","journal-title":"Autoimmun Rev"},{"key":"6333_CR38","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1136\/ard-2023-225371","volume":"83","author":"A-K Eiers","year":"2024","unstructured":"Eiers A-K, Vettorazzi S, Tuckermann JP (2024) Journey through discovery of 75 years glucocorticoids: evolution of our knowledge of glucocorticoid receptor mechanisms in rheumatic diseases. Ann Rheum Dis 83:1603\u20131613. https:\/\/doi.org\/10.1136\/ard-2023-225371","journal-title":"Ann Rheum Dis"},{"key":"6333_CR39","doi-asserted-by":"publisher","unstructured":"Suzuki K, Saito K, Akiyama M et al (2026) Effectiveness of tocilizumab for IgA vasculitis associated with idiopathic multicentric Castleman\u2019s disease:tTwo cases and literature review. Mod Rheumatol Case Rep 10. https:\/\/doi.org\/10.1093\/mrcr\/rxag014","DOI":"10.1093\/mrcr\/rxag014"},{"key":"6333_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00296-025-05880-w","volume":"45","author":"K Suzuki","year":"2025","unstructured":"Suzuki K, Akiyama M, Saito K et al (2025) Efficacy of tocilizumab monotherapy for autoimmune hemolytic anemia associated with idiopathic multicentric Castleman disease: a case-based review. Rheumatol Int 45:113. https:\/\/doi.org\/10.1007\/s00296-025-05880-w","journal-title":"Rheumatol Int"},{"key":"6333_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/25785826.2025.2547444","volume":"49","author":"K Suzuki","year":"2026","unstructured":"Suzuki K, Akiyama M, Saito K et al (2026) Successful tocilizumab monotherapy for multicentric Castleman disease complicated by rheumatoid arthritis and Sj\u00f6gren\u2019s disease: a case-based literature review. Immunol Med 49:107\u2013114. https:\/\/doi.org\/10.1080\/25785826.2025.2547444","journal-title":"Immunol Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06333-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06333-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06333-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:02:49Z","timestamp":1792699369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06333-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["6333"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06333-8","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"31 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"<b>Conflict of interest<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of this report was obtained from the patient.","order":3,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Acknowledgement:","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"293"}}